Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up
Introduction Currently, the majority of women worldwide with threatened preterm birth are treated with tocolytics. Although tocolytics can effectively delay birth for 48 hours, no tocolytic drug has convincingly been shown to improve neonatal outcomes and effects on long-term child development are u...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/7/e083600.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115305501622272 |
|---|---|
| author | Martijn A Oudijk Madelon van Wely Eva Pajkrt Job Klumper Aleid G van Wassenaer-Leemhuis Emilie V J van Limburg Stirum Janneke Van 't Hooft Larissa van der Windt |
| author_facet | Martijn A Oudijk Madelon van Wely Eva Pajkrt Job Klumper Aleid G van Wassenaer-Leemhuis Emilie V J van Limburg Stirum Janneke Van 't Hooft Larissa van der Windt |
| author_sort | Martijn A Oudijk |
| collection | DOAJ |
| description | Introduction Currently, the majority of women worldwide with threatened preterm birth are treated with tocolytics. Although tocolytics can effectively delay birth for 48 hours, no tocolytic drug has convincingly been shown to improve neonatal outcomes and effects on long-term child development are unknown. The aim of this follow-up study of a placebo controlled randomised trial is to investigate the long-term effects of atosiban administration in case of threatened preterm birth on child’s neurodevelopment and behaviour development, overall health and mortality.Methods and analysis This protocol concerns a follow-up study of the multicentre randomised double-blind placebo controlled APOSTEL 8 trial (NL61439.018.17, EudraCT-number 2017-001007-72). In this trial, women with threatened preterm birth (between 30 and 34 weeks of gestation) defined as uterine contractions with (1) a cervical length of <15 mm or (2) a cervical length of 15–30 mm and a positive fibronectin test or (3) in centres where cervical length measurement is not part of the local protocol: a positive fibronectin test or Actim-Partus test or (4) ruptured membranes, are randomised to atosiban or placebo for 48 hours. The primary outcome is a composite of perinatal mortality and severe neonatal morbidity. Children born to mothers who participated in the APOSTEL 8 study (n=760) will be eligible for follow-up at 4 years of corrected age and assessed using four parent-reported questionnaires. Primary outcomes are neurodevelopment and behaviour problems. Secondary outcomes are on child growth and general health. All outcomes will be compared between the atosiban and placebo group with OR and corresponding 95% CI. Analyses will be performed using the intention-to-treat approach.Ethics and dissemination The Medical Research Ethics Committee from Amsterdam UMC confirmed that de Medical Research Involving Human Subjects Act (Dutch WMO-law) did not apply to our study (W21_386 # 21.431). Results will be published in a peer-reviewed journal and shared with stakeholders and participants. This protocol is published before analysis of the results. |
| format | Article |
| id | doaj-art-eba65ee3ca9e48628508f3182568de92 |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-eba65ee3ca9e48628508f3182568de922025-08-20T02:36:35ZengBMJ Publishing GroupBMJ Open2044-60552024-07-0114710.1136/bmjopen-2023-083600Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-upMartijn A Oudijk0Madelon van Wely1Eva Pajkrt2Job Klumper3Aleid G van Wassenaer-Leemhuis4Emilie V J van Limburg Stirum5Janneke Van 't Hooft6Larissa van der Windt7Obstetrics, Amsterdam UMC Locatie De Boelelaan, Amsterdam, The Netherlands2 Amsterdam Reproduction and Development Research Institute, Amsterdam, The NetherlandsObstetrics and Gynaecology, Amsterdam UMC Locatie AMC, Amsterdam, The NetherlandsAmsterdam Reproduction and Development research institute, Amsterdam, NetherlandsAmsterdam Reproduction and Development research institute, Amsterdam, NetherlandsObstetrics and Gynaecology, Amsterdam UMC Locatie AMC, Amsterdam, The NetherlandsObstetrics and Gynaecology, Amsterdam UMC Locatie AMC, Amsterdam, The NetherlandsObstetrics and Gynaecology, Amsterdam UMC Locatie AMC, Amsterdam, The NetherlandsIntroduction Currently, the majority of women worldwide with threatened preterm birth are treated with tocolytics. Although tocolytics can effectively delay birth for 48 hours, no tocolytic drug has convincingly been shown to improve neonatal outcomes and effects on long-term child development are unknown. The aim of this follow-up study of a placebo controlled randomised trial is to investigate the long-term effects of atosiban administration in case of threatened preterm birth on child’s neurodevelopment and behaviour development, overall health and mortality.Methods and analysis This protocol concerns a follow-up study of the multicentre randomised double-blind placebo controlled APOSTEL 8 trial (NL61439.018.17, EudraCT-number 2017-001007-72). In this trial, women with threatened preterm birth (between 30 and 34 weeks of gestation) defined as uterine contractions with (1) a cervical length of <15 mm or (2) a cervical length of 15–30 mm and a positive fibronectin test or (3) in centres where cervical length measurement is not part of the local protocol: a positive fibronectin test or Actim-Partus test or (4) ruptured membranes, are randomised to atosiban or placebo for 48 hours. The primary outcome is a composite of perinatal mortality and severe neonatal morbidity. Children born to mothers who participated in the APOSTEL 8 study (n=760) will be eligible for follow-up at 4 years of corrected age and assessed using four parent-reported questionnaires. Primary outcomes are neurodevelopment and behaviour problems. Secondary outcomes are on child growth and general health. All outcomes will be compared between the atosiban and placebo group with OR and corresponding 95% CI. Analyses will be performed using the intention-to-treat approach.Ethics and dissemination The Medical Research Ethics Committee from Amsterdam UMC confirmed that de Medical Research Involving Human Subjects Act (Dutch WMO-law) did not apply to our study (W21_386 # 21.431). Results will be published in a peer-reviewed journal and shared with stakeholders and participants. This protocol is published before analysis of the results.https://bmjopen.bmj.com/content/14/7/e083600.full |
| spellingShingle | Martijn A Oudijk Madelon van Wely Eva Pajkrt Job Klumper Aleid G van Wassenaer-Leemhuis Emilie V J van Limburg Stirum Janneke Van 't Hooft Larissa van der Windt Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up BMJ Open |
| title | Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up |
| title_full | Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up |
| title_fullStr | Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up |
| title_full_unstemmed | Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up |
| title_short | Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up |
| title_sort | atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation study protocol of the 4 year apostel 8 follow up |
| url | https://bmjopen.bmj.com/content/14/7/e083600.full |
| work_keys_str_mv | AT martijnaoudijk atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup AT madelonvanwely atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup AT evapajkrt atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup AT jobklumper atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup AT aleidgvanwassenaerleemhuis atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup AT emilievjvanlimburgstirum atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup AT jannekevanthooft atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup AT larissavanderwindt atosibanversusplacebointhetreatmentofthreatenedpretermbirthbetween30and34weeksgestationstudyprotocolofthe4yearapostel8followup |